Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Exclusion Criteria

• •Use of a monoamine oxidase inhibitor (MAO-I) during or within 2 weeks of desipramine therapy
• •Concomitant therapy with any drugs shown to have major interactions with desipramine
• •Concurrent use of drugs that are contraindicated with desipramine
• •Myocardial infarction in preceding 4 weeks; history of uncontrolled cardiac arrhythmias or family history of sudden cardiac death; baseline corrected QT (QTc) \> 460 msec
• •Active alcohol abuse
• •Bipolar disorder
• •Untreated active major depression
• •History of seizures in the past 3 years
• •Pregnancy and lactation; refusal to use adequate contraception
• •Uncontrolled thyroid disease
• •GCSF or pegfilgrastim use within 14 days prior to enrollment
• •Bortezomib, Revlimid or thalidomide use within 7 days of enrollment
• •Patients with sickle cell disease